US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amplify EASI Tactical Growth ETF

21.07

0.0000

Volume:- -

Turnover:- -

Market Cap:10.54M

PE:- -

High:21.07

Open:21.07

Low:21.07

Close:21.07

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EASI"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EASI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EASI\",,,,,undefined,":{"symbol":"EASI","market":"US","secType":"STK","nameCN":"Amplify EASI Tactical Growth ETF","latestPrice":21.07,"timestamp":1593720000000,"preClose":21.07,"halted":4,"volume":0,"delay":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Delisted","change":0,"latestTime":"06-25 08:06:47 EDT","open":21.07,"high":21.07,"low":21.07,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750858200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":21.07,"sharesOutstanding":500000,"nav":21.1,"aum":0,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EASI\",,,,,undefined,":{"symbol":"EASI","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":21.07,"amplitude":0,"preClose":21.07,"low":21.07,"week52Low":18.71,"pbRate":"--","week52High":28.5068,"institutionHeld":0,"latestPrice":21.07,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":21.07},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EASI\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EASI\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529372760","title":"Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader","url":"https://stock-news.laohu8.com/highlight/detail?id=2529372760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529372760?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Data from the BroADen Phase 1b atopic dermatitis  patient trial expected to be reported in 4Q25. Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025. Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively. Two parallel Phase 2b clinical trials in moderate to severe AD and asthma patients are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.About KT-621KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-announces-first-patient-110000055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0541502299.USD","BK4096","BK4139","BK4115","KT","PN","LENZ","KYMR","EASI","LU0541501648.USD"],"gpt_icon":0},{"id":"2517441071","title":"New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2517441071","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517441071?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:00","pubTimestamp":1741442400,"startTime":"0","endTime":"0","summary":"Low disease activity was observed after a mean duration of 80 consecutive days off-treatment following success with VTAMA cream, with a mean weekly Peak Pruritus Numerical Rating Scale  score of 2.9 at the end of the treatment-free interval. Data presented as late breaker at 2025 American Academy of Dermatology  Annual Meeting. The new results demonstrate that, at the end of the first treatment-free interval, which lasted an average of 79.8 consecutive days, 84% of patients had a vIGA-AD score of 2 . Itch, which was assessed with the patient reported Peak Pruritus Numerical Rating Scale  score ranging from 0 to 10, remained low with a mean weekly PP-NRS score of 2.9. The mean Eczema Area and Severity Index  score was 3.4, indicating mild disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysis-organon-vtama-tapinarof-cream-140000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","EASI","BK4007","BK4559","OGN","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"2510859391","title":"Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2510859391","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510859391?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:00","pubTimestamp":1739188800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics  today announced that the U.S. Food and Drug Administration  has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells .In patients with moderate-to-severe atopic dermatitis, rezpegaldesleukin has been shown to rapidly improve measurable exploratory disease outcomes during a 12-week induction treatment phase and for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.1 Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-receives-fast-track-120000179.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-receives-fast-track-120000179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4104","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","EASI","FAST","BK4007","IE00B5TLWC47.USD","CSF","BSA","BK4567","BK4585","NKTR"],"gpt_icon":0},{"id":"2502857999","title":"Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2502857999","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502857999?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics  today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.Rezpegaldesleukin is a first-in-class interleukin-2 receptor  agonist that proliferates and activates regulatory T cells  with promising dose-dependent clinical activity in multiple skin disease settings. Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs and rapidly improved measurable exploratory disease outcomes in patients with moderate-to-severe atopic dermatitis that were largely durable for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.1 Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress in October 2023 .This trial was initiated in October ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000533.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKTR","CSF","BK4007","EASI","BSA"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EASI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-12-30","symbol":"EASI","amount":0.0709424,"name":"Amplify EASI Tactical Growth ETF","payableDate":"2019-12-31","currency":"USD","type":"dividend","dateTimestamp":1577682000000},{"market":"US","date":"2019-06-27","symbol":"EASI","amount":0.1005274,"name":"Amplify EASI Tactical Growth ETF","payableDate":"2019-06-28","currency":"USD","type":"dividend","dateTimestamp":1561608000000},{"market":"US","date":"2018-12-28","symbol":"EASI","amount":0.0997123,"name":"Amplify EASI Tactical Growth ETF","currency":"USD","type":"dividend","dateTimestamp":1545973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EASI\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-28","recordDate":null,"paymentDate":null,"value":0.0997123,"currency":"USD"},{"executeDate":"2019-06-27","recordDate":"2019-06-28","paymentDate":null,"value":0.1005274,"currency":"USD"},{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":null,"value":0.0709424,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EASI\",market:\"US\",delay:false,,,undefined,":{}}}